Why the study?
Does statin and ezetimibe therapy effectively reduce LDL cholesterol while managing liver enzyme elevation in a young adult with familial hypercholesterolemia?
Case Report (n=1)
Does statin and ezetimibe therapy effectively reduce LDL cholesterol while managing liver enzyme elevation in a young adult with familial hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
This case highlights the need for personalized management of familial hypercholesterolemia to balance cardiovascular risk reduction with potential statin-induced liver enzyme elevation.
Familial hypercholesterolemia (FH) is a hereditary condition associated with elevated cardiovascular risk, primarily due to increased LDL levels from a young age. In some cases, total cholesterol and triglycerides are also elevated. This case highlights the variable onset of FH within a family, elevated liver enzymes during statin therapy, and the need for a more aggressive treatment approach. Treatment included dose adjustments of statins and the addition of ezetimibe, with close monitoring for adverse events. Personalized management of FH is essential, balancing the need to control hyperlipidemia and reduce cardiovascular risk against potential liver enzyme elevation from statin therapy.
No takes yet. Share an insight, caveat, or question.
Hannah K Olle (2025) conducted a case report in Familial hypercholesterolemia (n=1). Simvastatin vs. Baseline was evaluated on LDL cholesterol (mg/dL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: